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A simple Baker’s cyst? Tocilizumab remits
paraneoplastic signs and controls growth
of IL-6-producing angiomatoid malignant
fibrous histiocytoma
SIR, A 47-year-old male presented with severe systemic
inflammatory response syndrome. A year previously he
had noticed a painless swelling in the right fossa poplitea
interpreted as Baker’s cyst. Laboratory analysis docu-
mented CRP (97 mg/l), ESR (102 mm/h), haemoglobin
(98 g/l), slightly elevated liver enzymes and hyperferritinae-
mia (1236mg/l), but no autoantibodies. Diagnostic workup
comprised bone marrow aspiration, liver biopsy, MRI
angiography of the thorax and abdomen, temporal artery
biopsy, upper and lower gastrointestinal (GI) endoscopy
and biopsies to search for Whipple’s disease, tuberculosis
and malignancy. Differential diagnoses such as adult
Still’s disease or occult vasculitis were discussed. Short
courses of glucocorticoids with 1 mg/kg body weight
tapered to 20 mg/day and MTX at 20 mg i.m. weekly
were ineffective. Treatment with infliximab at doses of
3.3 mg/kg body weight (in total 200 mg/kg) at weeks 0, 2
and 6 did not elicit any clinical benefit. CRP remained
unchanged (150 mg/l).
Three years later he was referred to our outpatient
clinic. His condition had worsened: haemoglobin 74 g/l,
CRP 156 mg/l, ESR 125 mm/h and polyclonal gammopa-
thy had developed (24.9 g; norm <14.6 g/l). Briefly, the
patient showed the classical symptoms and signs of un-
controlled IL-6 production [1]. The cellular source of this
cytokine remained enigmatic. The only inflammatory
tissue to be identified by imaging methods was the
Baker’s cyst, which was judged by experienced radiolo-
gists to be an uncomplicated cyst (Fig. 1A).
The patient agreed to off-label therapy using the IL-6-
neutralizing monoclonal antibody tocilizumab. He experi-
enced rapid and full remission. Laboratory parameters
and his physical condition normalized within a few
weeks. Infusions, the first two given at fortnightly intervals,
were continued at 4-week intervals at a dosage of 8 mg/kg
body weight.
One year later, in a further attempt to identify the source
of IL-6, the MRI of the knee was repeated (Fig. 1B).
Surprisingly, the morphology of the Baker’s cyst had chan-
ged considerably. A substantial part of the heterogeneous
tumour was replaced by a large cyst containing homoge-
neous liquid. We recommended surgical removal, stopped
tocilizumab and started to prospectively collect sera for
cytokine measurements. Histological analysis docu-
mented the unexpected diagnosis of angiomatoid malig-
nant fibrous histiocytoma (aMFH) with production of IL-6
by histiocytoma cells (Fig. 1CF) [2, 3]. Excision of the neo-
plasm resulted in complete and lasting remission. Cytokine
measurements continuously showed normal concentra-
tions of IL-1, TNF-a and soluble tumour necrosis factor
receptor (sTNFR). IL-6 was strongly elevated in synovial
fluid and normalized in sera within 8 weeks after surgery.
Many studies have reported elevated systemic levels of
proinflammatory cytokines and their antagonists in active
autoimmune and inflammatory diseases. Yet clinically it is
usually impossible to differentiate between the clinical
effects induced by each of the three cytokines. In this
case, however, IL-1b, TNF-a and sTNFR-75 remained
normal throughout the observation period, while IL-6
was highly elevated until surgery. In addition, blockade
of TNF-a using infliximab was completely ineffective with
respect to clinical signs as well as control of the acute
phase response (e.g. CRP levels), whereas blockade of
IL-6 resulted in rapid and lasting complete remission of
all pathology findings. In summary the clinical picture and
laboratory alterations represent the pleiotropic biological
effects of IL-6.
In contrast to its well-characterized effects in inflamma-
tion and immunity, the relevance of IL-6 as a mediator of
paraneoplastic signs is still unclear. This case is the first to
document a remission-inducing effect of IL-6 blockade
using tocilizumab in aMFH, thus identifying IL-6 as the
key pathogenic factor in the generation of paraneoplasias.
In addition to rapid and sustained clinical benefit, a
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striking finding was the change in morphology of the neo-
plasm in response to 1 year of IL-6 blockade. The MRI
suggested a decrease in aMFH volume replaced by a
large cyst. This tumour evolution could best be explained
by an autocrine growth effect of IL-6, as described for
example for multiple myeloma and prostate cancer [4].
The effect of IL-6 on differentiation of terminal B cells
into antibody-producing plasma cells was recognized
many years ago [1]. In multiple myelomas, substantial
quantities of IL-6 have been shown to be produced in a
paracrine fashion by surrounding stromal cells [5]. In our
case, immunohistochemistry showed impressive amounts
of IL-6 in aMFH cells, clinically reflected by polyclonal
gammopathy. However, IL-6 was virtually absent in
plasma cells. This pattern suggests that IL-6 produced
and secreted by the aMFH acted as a growth factor for
plasma cells as well as tumour cells. Documenting a high
density of polyclonal plasma cells in close proximity to
tumour cells supports this hypothesis, suggesting an ex-
planation for the formation of one tumour by two cell
populations of different origin.
Collectively, the patient’s history and described findings
show that the signs and symptoms of our case reflect the
effects of chronic IL-6 exposure. It identifies IL-6 as the
pathogenic factor for paraneoplastic signs and symptoms
in aMFH. Finally, it illustrates that complete response to
FIG. 1 MRI and histology of Baker’s cyst
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IL-6 blockade in a case resistant to TNF neutralization
should prompt a second diagnostic workup.
Rheumatology key message
. Neutralization of IL-6 by tocilizumab induces
complete clinical remission and controls the
growth of popliteal angiomatoid malignant fibrous
histiocytoma.
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Fulminant myocarditis and macrophage activation
syndrome secondary to adult-onset Still’s disease
successfully treated with tocilizumab
SIR, Adult-onset Still’s disease (AOSD) is a rare multisystem
inflammatory condition, the aetiology of which remains un-
known. Studies have shown that IL-1b, IL-6, IL-18, IFN-g
and TNF play pathogenic roles [1]. Commonly used biologic
agents in AOSD treatment include IL-1 receptor antagon-
ists and TNF-a blockers [2]. Treatment with tocilizumab as
both an initial agent and in multirefractory AOSD has been
reported [3]. Its use in macrophage activation syndrome
(MAS) has not.
Refractory or untreated AOSD may progress to MAS.
MAS results in excessive activation and expansion of
T lymphocytes and macrophagic histiocytes that exhibit
haemophagocytic activity. This leads to a massive
systemic inflammatory response associated with three
cardinal features: cytopenia, liver dysfunction and coagu-
lopathy. MAS is a life-threatening condition with reported
mortality rates of 2050% [4].
We report the case of a 32-year-old man who pre-
sented with recurrent pyrexia and arthralgia.
Investigations for infective causes including EBV, CMV
and atypical pneumonia were negative. Autoimmune
and HIV testing were also negative. Cardiac echo
showed a left ventricular ejection fraction (LVEF) of
>60%. Over a 4-week period he received numerous
courses of i.v. antibiotics, including gentamicin, tazocin,
meropenum, metronidazole and teicoplanin. However,
he continued to spike temperatures to 41.3C. CRP >
400 mg/l (normal <5) and a white cell count of 24 109/l
(normal 4.010.0) were persistently elevated.
Rheumatology evaluation elicited a rash and synovitis,
in keeping with AOSD (as classified using Yamaguchi
criteria) [5]. Serum ferritin was 11 683 mg/l (normal
1325).
An initial response was seen with prednisolone
40 mg/day. Over the following 48 h deterioration occurred,
with hypertriglyceridaemia, anaemia, thrombocytopenia,
tachycardia, hypotension, hypofibrinoginaemia and
hyperferritinaemia (peaking at 30 739mg/l). He required
transfer to the intensive care unit, where inotropic support
was commenced along with i.v. methylprednisolone and
anakinra.
An echocardiograph revealed a severely impaired LVEF
of 30%. High-sensitivity cardiac troponin peaked at
154 ng/l (normal <14), with clinical findings suggestive of
myocarditis.
A bone marrow biopsy indicated a hypercellular film
with myeloid hyperplasia and evidence of a left shift,
with reduced erythropoiesis. Plentiful macrophages ex-
hibiting haemophagocytosis were seen, in keeping with
MAS. No improvement was noted following 3 days of
anakinra. Our patient continued to decline, with increasing
inotropic support, worsening lactic acidosis and persist-
ent tachycardia.
Immunoglobulins, 70 g over 3 days, and ciclosporin
3 mg/kg were commenced. Treatment failure necessitated
tocilizumab 8 mg/kg. At this point intubation, vasopressor
support and dialysis were required. Repeat echocardiog-
raphy prior to tocilizumab infusion showed an estimated
ejection fraction of 20%, with severe global impairment,
a moderately dilated right ventricle, severely impaired
systolic function and a mildly dilated right atrium.
Cardiac arrest occurred within 48 h of the initial infusion
of tocilizumab, in the setting of worsening cardiogenic
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